09/19/2024
📣 Great news📣
ARE YOU over the age of 18, OVERWEIGHT & STRUGGLING TO LOSE WEIGHT? HAVE YOU BEEN WANTING TO TRY THE INJECTIONS THAT EVERYONE YOU KNOW HAS BEEN TAKING FOR WEIGHT LOSS ??? 🤔 YOU DON'T HAVE INSURANCE or YOUR INSURANCE REQUIRES A PRIOR AUTHORIZATION??? NO PROBLEM WE CAN HELP YOU!!🥰!
Eli Lilly, the manufacturer of Mounjaro & Zepbound, has lowered the prices of Zepbound exclusively for SELF PAY PATIENTS & for PATIENTS WHOSE INSURANCE WILL NOT PAY FOR WEIGHT LOSS MEDICATIONS without requiring a PRIOR AUTHORIZATION!!!🎉🎉🎉🎉🎉🎉
Zepbound is a FDA APPROVED WEEKLY injection for weight loss for patients (with a BMI of 30 or greater OR a BMI of 27 plus 1 weight related medical condition such as high blood pressure, high cholesterol, or sleep apnea) who do not have insurance OR whose insurance will not cover weight loss medications such as Zepbound!!! This discounted self pay price is available for Zepbound 2.5 mg and Zepbound 5mg single dose vials that are shipped straight from the manufacturer to your house! No prior authorization required! No worrying about the pharmacy not having the medication in stock! ❤️
Normally, this medicine costs $1000 + per month 😳😳😳😳 but now, Eli Lilly & Company/LillyDirect is making this a more affordable self pay option in order to help more people achieve their weight loss goals and live a healthier life ❤️
✨ PRICES OF MEDICATION✨
*2.5 MG OF ZEPBOUND FOR 1 MONTH USE(4 single use vials) : $399.00 ($99.75 per vial/week)🤩
*5MG of ZEPBOUND FOR 1 MONTH USE (4 single use vials): $549.00 ($137.25 per vial/week)🤩
Here are the details:
*Call our office, Burkett Family Practice, to schedule an initial appointment 912-592-0753 Office Phone OR TEXT the text line at 912-493-4774 include name & "requesting Zepbound Appointment" in the text
*Monthly office visits--->During the visit the prescription is sent to Eli Lilly/LillyDirect
*Eli Lilly/LillyDirect Representative calls patient within 24 hours to confirm address & for SELF PAY payment for medication ((NO PRIOR AUTHORIZATION REQUIRED))*******
* Zepbound for 4 weeks use shipped to your HOME. That's it! 👌
What are you waiting for??? You have ALL of that WEIGHT TO LOSE!!! HURRY & SCHEDULE YOUR APPOINTMENT TODAY & LET US HELP YOU DROP THE WEIGHT! 😍
****NOTICE: THIS IS NOT A COMPOUND! This is ZEPBOUND (Tirzepatide), The FDA APPROVED WEEKLY INJECTABLE WEIGHT LOSS MEDICATION. ****
Read more from Eli Lilly, the manufacturer of Zepbound:
"We are excited to share that the Zepbound single-dose vials are now here, further delivering on our promise to increase supply of Zepbound in the U.S.," said Patrik Jonsson, executive vice president, and president of Lilly Cardiometabolic Health and Lilly USA. "These new vials not only help us meet the high demand for our obesity medicine, but also broaden access for patients seeking a safe and effective treatment option. In a clinical study, the 5 mg maintenance dose helped patients achieve an average of 15% weight loss after 72 weeks of treatment and has been a powerful tool for millions of people with obesity looking to lose weight and keep it off."
Lilly has created a new self-pay pharmacy component of LillyDirect where patients with a valid, on-label prescription from the health care provider of their choice can purchase the vials. Distributing the vials via this channel ensures patients and providers can trust they are receiving genuine Lilly medicine, building on the company's efforts to help protect the public from the dangers posed by the proliferation of counterfeit, fake, unsafe or untested knock-offs of Lilly's medications. Lilly has also taken a vocal stance against the use of obesity medicine for cosmetic weight loss; a multi-step verification process will help ensure the vials are dispensed only to patients who have a valid, on-label electronic prescription from their health care provider. Patients can also purchase ancillary supplies, like syringes and needles, and will have access to important patient-friendly instructional materials on correctly administering the medicine via needle and syringe.
"People living with obesity have long been denied access to the essential treatment and care needed to manage this serious chronic disease," said James Zervos, chief operating officer, Obesity Action Coalit ion. "Expanding coverage and affordability of treatments is vital to people living with obesity. We commend Lilly for their leadership in offering an innovative solution that brings us closer to making equitable care a reality. Now, it's time for policymakers, employers and insurers to work with pharmaceutical companies to ensure no one is left behind in receiving the care they deserve and need."
A four-week supply of the 2.5 mg Zepbound single-dose vial is $399 ($99.75 per vial), and a four-week supply of the 5 mg dose is $549 ($137.25 per vial) – less than half the list price of other incretin medicines for obesity and in line with the Zepbound savings program for non-covered individuals. The self-pay channel enables a transparent price by removing third-party supply chain entities and allowing patients to access savings directly outside of insurance."
